We found that the percentage of CD4+ T cells producing IFNγ and TNFα were significantly reduced in the groups receiving ART plus PH-797804 compared to ART alone, whether the treatment is started on week 1 (p = 0.005 for TNFα and p = 0.02 for IFNγ) or week 6 post-infection (p = 0.04 for TNFα), (Fig 7A and 7B). The gene discussed is CD4; the disease is infection.